Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
FSHD region gene 2 family member M, pseudogene (FRG2MP) is classified as a pseudogene, meaning it is a segment of DNA that resembles a protein-coding gene but is generally nonfunctional and not transcribed into an active protein[5][3]. It is distinct from protein-coding members of the FSHD region gene family, such as FRG2, and does not participate in known biological processes, disease mechanisms, or therapeutic interventions[5][1]. Pseudogenes like FRG2MP are often remnants of evolutionary gene duplication events and are typically not involved in cellular signaling, metabolism, or disease pathogenesis. If you need structured variant or protein-coding target information, refer to FRG2 (FSHD region gene 2), which is related to muscular dystrophy but is distinct from FRG2MP[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on FSHD region gene 2 family member M, pseudogene (FRG2MP).